Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction

病例报告:TAS-102 和贝伐珠单抗双周维持治疗用于姑息性细胞减灭术后复发和转移性腹膜假性黏液瘤。

阅读:1

Abstract

INTRODUCTION: Recurrence of pseudomyxoma peritonei (PMP) with pulmonary and lymphatic metastases occurs only rarely in clinical practice, making the selection of an appropriate postoperative chemotherapy regimen essential for managing these complex cases. CASE PRESENTATION: We describe an 83-year-old woman with an appendiceal pseudomucinous tumor who developed a recurrence 2 years after initial surgery, presenting with bilateral lung metastases and multiple lymph node metastases. Palliative cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) was performed to relieve intestinal obstruction. Given the patient's advanced age and the complexity of the procedure, the completeness of the cytoreduction score was 2, and the peritoneal cancer index (PCI) was 10. Postoperative pathology confirmed a high-grade mucinous adenocarcinoma of appendiceal origin. After initiating a biweekly regimen of trifluridine/tipiracil (TAS-102) combined with bevacizumab, the patient achieved disease stabilization for approximately 5 months, with stable tumor marker levels and no evidence of radiological progression. CONCLUSION: This case underscores the therapeutic challenges of recurrent PMP with bilateral pulmonary and multiple lymph node metastases. A biweekly regimen of TAS-102 plus bevacizumab may represent a viable maintenance option when surgery and conventional chemotherapy regimens prove unsatisfactory.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。